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Abstract
Taking a nanoparticle (NP) from discovery to clinical translation has been slow compared to small
molecules, in part by the lack of systems that enable their precise engineering and rapid
optimization. In this work we have developed a microfluidic platform for the rapid, combinatorial
synthesis and optimization of NPs. The system takes in a number of NP precursors from which a
library of NPs with varying size, surface charge, target ligand density, and drug load is produced
in a reproducible manner. We rapidly synthesized 45 different formulations of poly(lactic-co-
glycolic acid)-b-poly(ethylene glycol) NPs of different size and surface composition, and screened
and ranked the NPs for their ability to evade macrophage uptake in vitro. Comparison of the
results to pharmacokinetic studies in vivo in mice revealed a correlation between in vitro screen
and in vivo behavior. Next, we selected NP synthesis parameters that resulted in longer blood half-
life and used the microfluidic platform to synthesize targeted NPs with varying targeting ligand
density (using a model targeting ligand against cancer cells). We screened NPs in vitro against
prostate cancer cells as well as macrophages, identifying one formulation that exhibited high
uptake by cancer cells yet similar macrophage uptake compared to non-targeted NPs. In vivo, the
selected targeted NPs showed a 3.5-fold increase in tumor accumulation in mice compared to non-
targeted NPs. The developed microfluidic platform in this work represents a tool that could
potentially accelerate the discovery and clinical translation of NPs.
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Nanoparticles (NPs) able to encapsulate and deliver thousands of drug molecules per
particle hold tremendous potential for treating various diseases such as cancer, inflammation
and infectious diseases.1 Despite the high level of activity and enthusiasm focused on the
development of NP therapeutics over the past 30 years, very few NP formulations have
reached clinical translation and human impact.2 In fact, while there are myriads of proof-of-
concept studies presenting novel NPs that target and kill cancer cells, there are significantly
fewer examples where the engineering and optimization is carried out to reach clinical
translation. In part, the challenge lies in the complexity of NP optimization, since for every
disease type it is necessary to find the optimal interplay of biophysicochemical parameters
(e.g. size, charge, surface composition, etc.) that simultaneously confer molecular targeting,
immune evasion and controlled drug release.3, 4 In addition, technology platforms for the
rapid synthesis of NPs with a wide range of properties in a reproducible manner are only
now starting to emerge.5-7
Microfluidics, the science and technology of manipulating nanoliter volumes in microscale
fluidic channels, has impacted a range of applications including biological analysis,
chemical synthesis, single cell analysis, and tissue engineering.8 In nanomedicine,
microfluidics has enabled the synthesis of NPs with narrower size distributions, improved
batch-to-batch reproducibility, and higher drug loadings.9, 10 Some key advantages of
microfluidics include simplicity and reproducibility of device fabrication, and potentially
lower cost of materials due to the ability to handle small volumes. These advantages make
the use of microfluidics ideal for the development of a platform that enables rapid synthesis
and optimization of NPs.11
In the present work, inspired by the rapid, combinatorial synthesis of small molecules12, 13
and novel biomaterials,14 we have developed a microfluidic platform for the rapid,
combinatorial synthesis of NPs. Previously, we developed a microfluidic device that used
3D hydrodynamic focusing to create NPs of different sizes, in a reproducible manner, using
4 different polymeric precursors.15 However, the device did not have the capability to mix
precursors prior to nanoprecipitation and was not amenable to high-throughput screening.
Here, we developed a fully integrated microfluidic device with a multi-inlet micromixer16 to
allow for programmable and systematic mixing of a large number of precursors before
nanoprecipitation occurs. As a proof of concept, we demonstrate that this system allows for
the synthesis of NPs with a wide range of properties, with batch-to-batch reproducibility, by
combining over 15 different NP precursors in different ratios. For each formulation, we
produced merely tens of micrograms of NPs, enough for rapid in vitro evaluation. Next, we
show the rapid NP evaluation capabilities of the platform by synthesizing 45 different
formulations with different sizes and surface composition, screening them for macrophage
uptake in vitro, and comparing the results with in vivo pharmacokinetic studies. Finally, we
use the microfluidic system to synthesize targeted and non-targeted NPs with the same size
and charge, and compare their tumor accumulation in vivo. These studies have broad
implications in nanomedicine, where such a platform could be used to rapidly optimize
promising novel lipid and polymeric NPs and move them quickly to pre-clinical studies.
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Results
Microfluidic Platform for Rapid Development of NPs
The microfluidic platform is composed of a multi-inlet mixing unit and a synthesis unit that
operate in continuous flow mode (Figure 1A). In the mixing unit, a number of NP precursors
dissolved in organic solvent are introduced in different inlets and mixed at various ratios in a
3D micromixer16 (Figure 1B). In the synthesis unit, each precursor combination is rapidly
mixed with water using a technique called 3D hydrodynamic flow focusing, where the NP
precursors are squeezed three-dimensionally to a thin stream that rapidly diffuses with
water, resulting in self-assembly of NPs through the process of nanoprecipitation15 (Figure
1C). Each mixing unit inlet is connected to a syringe driven by a programmable syringe
pump, which allows for precise control over the ratio of precursors that ultimately defines
the physicochemical properties of the resulting NP. The flow rates of the input NP
precursors can be altered periodically, resulting in sequential synthesis of a library of NPs
with distinct properties and compositions. A photograph of the device is presented in Figure
1D and a TEM micrograph of representative NPs obtained with this system is shown in
Figure 1E. To synthesize a diverse library of NPs, we used 15 different precursors based on
poly(lactic-co-glycolic) acid-b-polyethylene glycol (PLGA-PEG) (Table S1). These
included PLGA-PEG with different end-functional groups to control surface charge (e.g.
amine, carboxyl, methoxy), PLGA MWs to control NP size (10, 27, 45, and 95 kDa), and
PEG MWs to control hydrophilicity (2, 5, and 10 kDa); PLGA-PEG functionalized with
S,S-2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid, a small-molecule ligand
(LIG) that targets Prostate Specific Membrane Antigen (PSMA) receptors overexpressed in
prostate cancer cells;17, 18 and PLGA with different fluorescent probes for NP detection.
Tuning NP Properties by Mixing of Precursors in Distinct Ratios
To demonstrate the versatility of the platform, we synthesized a number of NPs spanning a
wide range of physicochemical properties by strategically varying the ratios of different NP
precursors. For instance, to vary the NP size we mixed PLGA-PEG with different PLGA
MW ranging from 10 kDa to 95 kDa, resulting in sizes ranging from 25 nm up to 200 nm
(Figure 2A). For varying surface charge, previous studies reported that NPs comprised of
PLGA-PEG-NH2 exhibited a zeta potential of +10 to 15 mV while NPs comprised of
PLGA-PEG-COOH exhibited a zeta potential of −10 to −15 mV, and those comprised of
PLGA-PEG-OCH3 remained neutral.19, 20 Therefore, by mixing polymers solutions
containing, for instance, OCH3 and COOH, it was possible to tune the surface charge from
neutral to highly negative (Figure 2B). For varying surface ligand density, we mixed PLGA-
PEG-LIG with unmodified PLGA-PEG at different ratios resulting in estimated ligand
densities on the order of 103-105 ligands/μm2 (i.e. ~101-103 ligands per NP) (Figure 2C).21
Finally, for varying the final drug loading of the NPs, using docetaxel as model drug, we
varied both the initial drug loading and the polymer concentration in acetonitrile—factors
that were previously shown to affect drug loading.22, 23 In this case, one stream contained
the drug, another contained PLGA-PEG of a specific MW at 50 mg/mL, and plain
acetonitrile was in a third stream to modify the concentration from 50 mg/mL down to 10
mg/mL (Figure 2D). Finally, these NPs were prepared with excellent batch-to-batch
reproducibility and much narrower size distributions compared to conventional bulk
synthesis (Figure S2). These results show that it is possible to reproducibly create a library
of NPs spanning a broad range of NP properties by combinatorially mixing a small number
of NP precursors, mostly derived from PLGA-PEG-based polymers.
Rapid Development and Screening of NP Library
Next, to show the utility of our system for rapid synthesis and screening of NPs, we selected
7 polymers containing different PLGA and PEG MWs mentioned above as well as free
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PLGA (45 kDa) to synthesize a library of NPs comprised of 45 distinct formulations with
different sizes and PEG coverage (see Table S2). We focused on identifying optimal non-
targeted NPs by varying three key parameters known to affect in vivo NP behavior:24, 25 1)
NP size, 2) PEG coverage, and 3) PEG molecular weight. While NP charge is known to also
affect the blood circulation half-life, we chose PEG with neutral terminal groups based on
our previous studies reporting that charged NPs tend to induce complement activation more
readily than neutral NPs.20, 26 For the screening, we used an established in vitro macrophage
binding and uptake assay,21 in which the extent of interaction between macrophages and
NPs depends on the NP physicochemical properties. In this assay, fluorescently labeled NPs
were incubated with macrophages in 96-wells plates and then analyzed with flow cytometry
using a high-throughput robotic sampler. Depending on the particle dosing per well and
number of repeats per formulation, the time to synthesize 45 formulations may take from
minutes to hours. In the present case, the synthesis of 45 NP formulations that were dosed at
100 μg of NPs per well at n = 3, required approximately 70 min—whereas by conventional
pipetting it could take up to 10 times longer7 and would likely be less reproducible.
Figure 3A shows the fluorescence intensity associated with NP binding and uptake by
macrophages for the 45 formulations. For each formulation, we also measured NP size,
estimated the PEG weight % from the input flow rates, and reported the average PEG length
(Table S2). The results indicate that NP formulations of small size (25-30 nm), relatively
high PEG wt. % (up to 33%) and longer PEG molecules (up to 10 kDa) are taken up least by
macrophages, which agrees with previous results reported on PEG-functionalized NPs.24, 27
Interestingly, it was observed that NP size was a key determinant in macrophage association
more so than PEG coverage. For instance, a 30 nm NP with PEG length of 5 kDa was taken
up less than a 50 nm NP with length 10 kDa. These results not only provided insight into the
behavior of NPs exposed to macrophages, but it also demonstrated that coupling rapid
microfluidic NP synthesis with conventional high-throughput screening methods enabled a
large number of NPs to be evaluated in a relatively short amount of time.
In vivo, NPs tend to be taken up by the mononuclear phagocytic system (MPS) mostly in the
liver and the spleen, which directly affects their circulation time.28 Consequently, it would
be expected that NP uptake by macrophages in vitro serves as a first indication of the NP
pharmacokinetics (PK) in vivo. To evaluate this hypothesis, we selected 4 representative
formulations showing different macrophage uptake behaviors ranging from minimal to
maximal, and investigated their PK profile in vivo. For this experiment, we increased the
scale of production two orders of magnitude from hundreds of micrograms to tens of
milligrams by simply programming the microfluidic system to run for a longer period of
time (~ 50 min per formulation). Interestingly, the NP properties remained essentially
identical across batches of different scales, which we consider a key advantage of the
system. Figure 3B shows the PK profile of selected NP formulations that exhibited
increasing macrophage uptake. Analysis of the PK profile revealed that the NP formulation
with the lowest macrophage uptake had the longest half-life (Figure 3C) and greatest area
under the curve (AUC, which is the integral of the concentration over time, expressed as %
of initial dose (ID) x time) (Figure 3D). These results confirm the hypothesis that NPs with
higher macrophage interactions tend to circulate in blood for a shorter amount of time.29-31
Screening of NPs with Different Targeting Ligand Densities
In addition to NP physicochemical properties including size, surface charge, and PEG
coverage, targeting ligands can be used in an attempt to preferentially accumulate NPs in
target tissues.26 Based on this, we used the microfluidic system to synthesize targeted NPs
with different targeting ligand densities, with the goal of finding one with maximum
targeting ligand-mediated specific uptake with minimum macrophage uptake. Similar to
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previous experiments, the model targeting ligand used was LIG, which targets PSMA
receptors overexpressed on LNCaP cells (a model prostate cancer cell line).17, 18 We started
with the parameters identified in the previous screen that minimized macrophage uptake, i.e.
low NP size and high PEG coverage both obtained by using PLGA27K-PEG5K as initial
precursor in formulation NP-2. We added increasing amounts of PLGA45K-PEG5K-LIG to
the combination of precursors used for synthesis of NP-2 to rapidly synthesize targeted NPs
(TNPs) with different ligand densities, followed by screening them in vitro against LNCaP
cells as well as macrophages. Figures 4A and 4B show the cancer cell and macrophage
uptake, respectively, for five different formulations containing increasing amounts of
ligands on the NP surface. The results indicated that when adding up to 14 mole % of
PLGA-PEG-LIG with respect to total PLGA-PEG plus PLGA-PEG-LIG to the NP
formulation, a significant increase in uptake by cancer cells was observed with only a small
difference in macrophage uptake compared to non-targeted NPs (NT-NPs). Beyond 14 mol
% PLGA-PEG-LIG, a significant increase in macrophage uptake was observed.
Interestingly, TNPs with up to 14 mole % of PLGA-PEG-LIG exhibited essentially the same
average size and charge as those with unmodified PLGA-PEG (40 nm and −0.5 mV) (Figure
S2), thus providing an attractive model to compare the tumor accumulation of TNPs versus
NT-NPs.
Next, we used TNP with 14 mol% formulation (corresponding to approximately 200 ligands
per NP), and performed in vivo studies to compare their biodistribution and tumor
accumulation with NT-NPs. For the in vivo studies, we implanted 1×107 LNCaP cells in the
flank of the mouse and let the tumor grow for 3-4 weeks to a size of approximately 400-600
mm3. TNPs and NT-NPs labeled with Alexa Fluor 647 were injected via tail vein. After 24 h
the animals were sacrificed and the fluorescence in the organs was measured (Figures 4C).
While the fluorescence signal in most of the organs was similar for both formulations, two
main differences were observed for the spleen and tumor, where TNP showed significantly
higher accumulation in tumor and less in the spleen versus the NT-NPs. In fact, the signal
accumulation of TNPs in the tumor was close to 3.5-fold that of the NT-NP (Figure 4D).
Discussion
While we report here the synthesis of PLGA-PEG NPs, any polymer and polymer-ligand
conjugate that undergo self-assembly by nanoprecipitation26 in water could potentially be
synthesized using the microfluidic platform, and any drug that preferably interacts with the
polymer versus water could be encapsulated. However, the organic solvent used must be
compatible with the polymer, ligand, and drug, and polydimethylsiloxane (PDMS) used for
device fabrication.
The microfluidic platform allows for synthesis of more homogeneous, tunable NPs.11,15,33
Three key determinants of the NP size and polydispersity are (1) the polymer properties (e.g.
chemical structure, molecular weight), (2) degree of interaction of polymer with organic
solvent, and (3) the mixing time of organic solution and water during nanoprecipitation.33
While there are a number of ways to control NP size, our results indicate that by simply
mixing polymers having different MW of the hydrophobic block at different ratios, one can
have tighter control over a wide range of NP sizes. When mixing two polymers with
different PLGA MW, we observed that it is the polymer with higher MW that tends to have
a stronger contribution to the final NP size. Prior work has shown that homogeneous NPs
are obtained when the mixing timescale is smaller than that of the polymer aggregation
timescale (typically in the several millisecond range).32, 33 Our studies reported here and
previously15 revealed that while small MW weight polymers (<30 kDa) were not very
sensitive to mixing time, nanoprecipitation of high MW (>50 kDa) polymers exhibited
distinct improvement in polydispersity upon rapid mixing. Nanoprecipitation involves
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nucleation of NPs and aggregation of polymers into NPs, resulting in the final size and
polydispersity.34 Rapid mixing results in rapid solvent exchange and, therefore, the rate of
nucleation is expected to be enhanced due to the higher supersaturation, directly contributing
to decrease in size. In addition, the barrier to insertion and aggregation depends on the
solvent quality. Rapid transition to an aqueous solution is expected to increase the barrier
required for insertion of polymers into NPs and the aggregation of NPs, due to the formation
of a hydrophilic PEG layer on the surface. In the absence of complete solvent change, the
PEG barrier may be insufficient to prevent aggregation, resulting in “tails” of larger NPs in
the size distribution formed by aggregation of NPs. Our results suggest that this effect is
prominent when the PLGA MW is high, which involves a larger driving force for
aggregation due to the high MW hydrophobic block and a less effective barrier to
aggregation due to the relatively low fraction of PEG. As a result, NPs prepared from high
MW polymers tend to exhibit a greater sensitivity to mixing time. Although models have
been developed to describe this process,34 full details of the evolution of the barrier strength
remain elusive.
We evaluated the NPs in vitro for macrophage uptake, which had two purposes: (a) to
investigate the correlation between phagocytosis in vitro and blood clearance in vivo with
the aim of rapid identification of NPs that would have lower probability of being successful
in vivo (which saves significant time and resources). (b) To demonstrate the broad
applicability of the platform by integrating it with a conventional NP assay; this can
potentially be extended to high-throughput assays for other key NP biological properties
such as complement activation, cell uptake, and cell cytotoxicity. The results indicate that
NPs with significantly distinct macrophage uptake would likely have distinct
pharmacokinetic profiles (though NPs with similar macrophage uptake would not
necessarily exhibit similar pharmacokinetics). In addition, while it is known that NP size as
well as PEG MW and PEG wt% on NPs are factors that affect macrophage uptake, the
results indicate that, over the range studied, NP size was a greater contributor to macrophage
uptake than PEG MW and PEG wt% (i.e. a smaller NP with shorter PEG would be taken up
less than a larger NP with longer PEG). Consequently, our method to reproducibly
synthesize NPs together with the in vitro macrophage uptake assay might be useful to
quickly select promising NP formulations for pre-clinical evaluation with respect to
circulation time, as well as to identify which formulations have a high probability of not
working in vivo—which can save significant amount of time and resources later on.
Integration of the microfluidic system with conventional high-throughput screening methods
demonstrates versatility of the platform as well as broad applicability. The simple design of
the device, the use of ‘off the shelf’ materials such as PDMS, syringe pumps, 96-well plates,
etc., and the integration with high-throughput flow cytometry and screening in multi-well
plates, makes it a technology and an approach relatively easy to replicate and adopt by other
laboratories. Some limitations of the device are the time (~hrs) required to produce NPs at a
scale larger than few milligrams. To solve this challenge, one can parallelize the
channels,35, 36 or use mixers that have inherently high flow rates.6, 32 Similarly, the PDMS
device tends to become less robust at high flow rates due to the high pressure exerted. This
problem may be addressed by fabricating devices from stronger materials such as glass.
In this study we have identified the optimal ligand density that would result in minimal NP
recognition by macrophages (which positively impacts the circulation time of NPs), and
maximal uptake by LNCaP cells (which positively impacts the tumor accumulation of NPs).
Assuming a NP density of 1.27 g/mL, the corresponding ligand density for the optimal NP is
estimated at ~200 ligands/NP assuming that all ligands are expressed on the NP surface.21
Since “optimal” is defined in the context of a desired effect, we expect that the optimal
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ligand density would vary with choice of ligand, tumor/organ being targeted, and the cell
type within the tumor/organ.
The use of a small molecule, hydrophilic, and neutral targeting ligand, together with the
ability to control the number of ligands on the surface of NPs, and the rapid mixing
environment during self-assembly enable the one-step self-assembly of targeted NPs with
similar size and charge than non-targeted NPs. While previous studies have investigated the
impact of targeting on NP tumor accumulation,26, 37 any conclusive outcome is
compromised by the differences in other properties of NPs (e.g. increase in size) when a
targeting ligand is added. Microfluidics enables synthesis of homogeneous NPs, and the
impact of adding a longer MW polymer precursor on NP size is minimal compared to
conventional synthesis where NP size is significantly altered.33 We can thus directly assess
the impact of targeting as the TNPs and NT-NPs in this study had the same size and zeta
potential. These results, therefore, indicate that the incorporation of a targeting ligand on the
surface of NPs does have a significant impact in the accumulation of NPs in the tumor when
compared to non-targeted NPs with similar biophysicochemical properties (e.g. size, and
zeta potential). While further studies should be carried out to investigate the kinetics of
tumor accumulation, these preliminary results illustrate the importance of active targeting
for tumor accumulation, and demonstrate the benefit of the microfluidic platform to rapidly
identify a promising targeted NP candidate.
Conclusion
We reported a new microfluidic platform for the rapid, combinatorial synthesis of targeted
polymeric NPs. It was first demonstrated that NPs with a wide range of properties can be
generated by making a small library comprised of NPs with size from 25-200 nm, zeta
potential from −20 to +20 mV, ligand density from 0 to ~105 ligands/μm2, and drug loading
from 0 to 5%. Subsequently, we showed the rapid NP development capabilities of the
system by synthesizing 45 NP formulations of different sizes and PEG coverage, and
screened them against macrophage uptake in vitro. Finally we investigated the relation
between in vitro macrophage uptake and in vivo pharmacokinetics, where low macrophage
uptake correlated with longer circulation time. Building upon the in vitro macrophage
uptake screen, we synthesized and screened targeted NPs to identify a formulation that
maximized specific uptake in vitro while minimizing macrophage uptake. We also
investigated the tumor accumulation of TNPs versus NT-NPs of essentially identical
biophysicochemical properties, where the TNPs showed 3.5-fold accumulation in tumor
versus non-targeted ones. Three key advantages of our system over existing bulk synthesis
include (i) from a small set of NP precursors one can rapidly synthesize a NP library with a
wide range of distinct physicochemical properties; (ii) the NPs prepared have high batch-to-
batch reproducibility; (iii) NPs can be prepared at different scales (e.g. microgram versus
milligram) without varying substantially the NP properties. These advantages allow for both
in vitro and in vivo screening with the goals of either accelerating the clinical translation of a
specific formulation or obtaining deeper fundamental understanding on the correlation of NP
properties and biological behavior.
Materials and Methods
Materials
PLGA-PEG with PLGA MWs of 27, 45, and 95 kDa were purchased from Boehringer
Ingelheim GmbH (Germany). PLGA-PEG with PLGA MW of 10k Da was purchased from
Akina Inc (West Lafayette, IN). Unmodified PLGA with MWs of 15k, 45k, and 70k were
purchased from Lactel (Pelham, AL). All PEG-based polymers were purchased from Laysan
Bio, Inc (Arab, AL). Alexa fluor probes as well as all biological reagents were purchased
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from Invitrogen (Carlsbad, CA) and. Cell lines were purchased from ATCC (Manassas,
VA). Balb/c mice were purchased from Charles River Laboratories (Wilmington, MA). All
solvents were purchased from Sigma-Aldrich (St. Louis, MO). Docetaxel was purchased
from LC Laboratories (Woburn, MA). Finally, SU-8 and PDMS were purchased from
Microchem (Newton, MA) and Dow Corning (Midland, MI).
Fabrication of Microfluidic System
The prototypical system was manufactured using standard soft lithography, described
previously.33 Briefly, SU-8 resist was lithographically patterned on a 4″ silicon wafer to
fabricate a master mold. Polydimethylsiloxane (PDMS, Sylgard 184) monomer and curing
agent were mixed in a ratio of 10:1 by weight, poured over the silicon master mold, and
degassed. After curing at 100 °C for 60 min, the PDMS cast was carefully removed from the
mold. The multi-inlet mixing unit was composed of two layers that were aligned and bonded
together after placing each layer in plasma for 30 s. Inlets and outlet holes were drilled
followed by bonding the PDMS to a glass slide using air plasma. NP synthesis unit was
composed of a single layer with inlet holes precisely drilled next to each other to achieve 3D
flow focusing.15 Typical channel dimensions used in the NP synthesis experiments had a
width of 100 μm and a height of 60 μm for the vertical focusing part and had a width of 20
μm for the horizontal focusing part, or precipitation channel. The outlet of the mixer unit
was connected to the middle inlet in the NP synthesis unit while the side inlets were
connected to syringes containing acetonitrile.
Nanoparticle Precursors
PLGA-PEG-LIG was synthesized as previously reported.18 Briefly, LIG was dissolved in
400 μL of dimethylformamide (DMF) and allowed to react with tBOC-NH-PEG-NHS in the
presence of N,N-diisopropylethylamine (DIEA). The reaction product was dialyzed for 24 h
in water to remove unreacted LIG, then lyophilized, and finally resuspended in
trifluoroacetic acid (TFA) to remove tBOC. Subsequently, PEG-LIG was dried and
dissolved in DMSO. In parallel, PLGACOOH was allowed to react with N-
hydroxysuccinimide (NHS) in the presence of 1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide (EDC) in dichloromethane (DCM). The resulting PLGANHS was dried and
dissolved in DMSO. Finally, PEG-LIG and PLGA-NHS in DMSO were mixed with DIEA,
allowed to react, precipitated in cold methanol, and dried under vacuum. Synthesis of
PLGA-PEG was accomplished using EDC/NHS chemistry.22 For PLGA-PEG with PEG of
different PEG MWs and PEG functional groups was accomplished by conjugation of PLGA
homopolymer with a carboxylate end-group to a monofucntional methoxy-PEGx-NH2,
where x indicates PEG MW (2, 5, and 10 kDa). For PLGA-PEG functionalized with
carboxyl and amine groups, difunctional NH2-PEG-COOH and NH2-PEG-NH2 were used,
respectively. Briefly, PLGA-Carboxylate was dissolved in DCM, followed by the addition
of NHS and EDC to the solution. After 2 h the resulting product, PLGA-NHS, was
precipitated in ethyl ether/methanol, collected by centrifugation, and drying under vacuum.
PLGA–NHS was dissolved in DCM followed by addition of monofuctional or difunctional
PEG together with DIEA. The resulting PLGA-PEG block copolymer was precipitated with
ether/methanol and washed with the same solvent to remove unreacted PEG.
The synthesis of PLGA-Alexa488 and PLGA-Alexa647 were accomplished by the
conjugation of an activated PLGA-COOH with Alexa Fluor-488/647 Cadaverine through
EDC/NHS conjugation. First, Alexa Fluor-488/647 was dissolved in 1 mL of DMF.
Concurrently, PLGACOOH (was mixed with EDC and NHS in 500 μL of DMF. Finally,
PLGA solution was reacted with Alexa Fluor-488/647 solution for 16 h at room
temperature. The reaction product was precipitated in ice cold methanol and dried under
vacuum. All polymers were characterized with gel permeation chromatography (GPC) as
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well as nuclear magnetic resonance (NMR), to confirm molecular weight and chemical
structure, respectively.
Nanoparticle Synthesis and Characterization
NPs were prepared by nanoprecipitation.15 Briefly, the organic stream (polymers and drugs)
was run at 7 μL/min, vertical sheath streams (acetonitrile) were run at 3 μL/min while
maintaining a total aqueous flow rate of 50 μL/min. NPs were collected at the outlet stream
and washed three times with water using Amicon centrifugation filtration membrane to
remove excess drugs and organic solvents. Dynamic light scattering (DLS) was used to
determine particle size and size distribution, using a Zetasizer Nano ZS instrument (Malvern
Instruments Ltd., U.K.). Particle visualization was carried out through TEM (JEOL 2011
instrument at an acceleration voltage of 200 kV). Drug loading and encapsulation efficiency
(EE) were determined by quantifying the amount of docetaxel in the NP by dissolving them
in a 50/50 acetonitrile/water solution immediately after synthesis and vortexing for several
hours to induce NP dissociation. The amount of docetaxel inside the NPs was quantitated by
HPLC with a UV reader at a wavelength of 267 nm. A calibration curve with known
concentrations of docetaxel was prepared, and the amount of drug encapsulated in the NPs
was calculated accordingly.
Nanoparticle Binding and Uptake by RAW264.7 and LNCaP cells
RAW 264.7 cells were cultured in DMEM medium with 10% fetal bovine serum, 50 units/
mL penicillin and 50 mg/mL streptomycin. LNCaP cells were cultured in RPMI medium
with 10% fetal bovine serum, 50 units/mL penicillin and 50 mg/mL streptomycin. Cells
were seeded at a density of 50,000 cells per well on a 24-well plate. After 24 h, the cell
medium was removed and replaced with NPs dissolved in the same medium at a
concentration of 1 mg/mL. Cells and NPs were incubated for 4 h for the case of RAW 264.7
and LNCaP, followed by three washes with 1% BSA solution in PBS to remove excess NPs.
RAW264.7 cells were removed from the plate using a cell scraper and centrifuged, while
LNCaP cells were treated with trypsin, removed from the plate, and centrifuged. The
resultant cell pellets were reconstituted in 250 μL of PBS and placed on a 96-well plate for
FACS analysis. Flow cytometry analysis was performed on a BD Biosciences LSR II with
High-Throughput sampler (HTS) option, with 10,000 cells were collected for each
measurement.
Pharmacokinetics and Biodistribution Studies
All animal studies were conducted under the supervision of MIT’s Division of Comparative
Medicine in compliance with the NIH’s Principles of Laboratory Animal Care. For
pharmacokinetic studies, wild-type Balb/c mice were used. Fluorescently labeled NPs (with
Alexa-647) were injected via tail vein in groups of 4 mice per formulation. At different time
points, a few microliters of blood were sampled from the mouse and the fluorescence
measured using IVIS imaging system. As a control, blood from mice with no NPs injected
was used and the background fluorescence was measured. Plasma half-life was determined
using the method described by H. Cabral et al,38 whereas area under the curve was
calculated by integrating the PK profile using the trapezoid method.
For biodistribution studies, the xenograft tumor-bearing mouse model was constructed by
inoculating 1×107 cells/0.2 mL mixed with an equal volume of ice-cold matrigel. The cells
employed were luciferase-expressing LNCaP cells (LNCap-luc), which allow for
continuously monitoring and control the growth of the tumor by whole-animal luminescent
imagining. Tumors were allowed to grow for 3-4 weeks until they reach a relative
luminescence intensity of ~1.5-2.5×106 photons/s which corresponds to tumor sizes of
400-600mm3. Mice were randomized into targeted NPs and non-targeted NPs treatment
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groups (n = 5 each). To each mouse, 200 μL of a solution containing 5 mg/mL of NPs
labeled with Alexa-647 were injected via tail vein. The fluorescence of each formulation did
not vary significantly between each dose or between NTNP and TNP. After 24 h the animals
were sacrificed, main organs were excised, weighted, and their fluorescence was measured
using IVIS spectrum-bioluminescent and fluorescent imaging system (Xenogen
Corporation).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Microfluidic platform for rapid synthesis of NPs
(A) Schematic of system where NP precursors enter a multi-inlet mixer at different ratios
producing a library of NPs upon self-assembly. (B) Mixer in operation showing complete
mixing of streams at the end of the mixer. Scale bar = 200 μm, (C) Image of hydrodynamic
flow-focusing where NPs self-assemble through nanoprecipitation. Scale bar = 20 μm. (D)
Photograph of microfluidic devices for mixing of NP precursors and NP synthesis. (E)
Image of representative NPs produced by the system. Scale bar = 50 nm.
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Figure 2. Synthesis of PLGA-PEG NPs with control over physicochemical properties
(A) Variation of NP size by mixing polymers with different PLGA MW. 1 – PLGA10K-
PEG5K; 2 – PLGA27K-PEG5K; 3 – PLGA45K-PEG5K; 4 – PLGA95K-PEG5K. (B) Variation
of NP surface charge by mixing polymers with different end functional group on the PEG
block. Carboxyl group ( – COOH) is negatively charged while methoxy group (-OCH3) is
neutral. 1 – PLGA45K-PEG5KOCH3; 2 – PLGA45K-PEG5K-COOH. (C) Variation of
targeting ligand density by mixing polymers functionalized with targeting ligand (PLGA-
PEG-LIG) together with unmodified polymer. 1 – PLGA27K-PEG5K; 2 – PLGA45K-PEG5K-
LIG. (D). Variation of drug loading by mixing a polymer at a high concentration (50 mg/
mL) with different ratios of drug (to vary initial drug loading) and plain acetonitrile (to vary
concentration). 1 – PLGA27K-PEG5K; 2 – docetaxel; 3 – acetonitrile. Blue bar, initial drug
loading of 5%; red bar, initial drug loading of 10%. Legend: Blue block = PEG; Red block =
PLGA. Error bars denote ±S.D.
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Figure 3. Synthesis and screening of 45 NPs with different sizes and PEG coverage
(A) Fluorescence intensity (FI) of macrophages associated with Alexa-488-labeled NPs.
Heat map indicating extent of size, PEG weight % and average PEG length for each
formulation. (B) Pharmacokinetic profile measured by the relative fluorescence of
Alexa-647-labeled NPs in blood. (C) Circulation half-life and (D) area under the curve of
selected formulations with increasing macrophage binding and uptake. See Table S2 for
details of the NP formulations. Error bars denote ±S.D.
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Figure 4. Comparison of biodistribution and tumor accumulation of targeted and non -targeted
NPs with similar biophysicochemical properties
(A & B) Fluorescence intensity of Alexa-488 labeled targeted NPs associated with LNCaP
cells (A) and macrophages (B) normalized by that of non-targeted NPs. Blue and red bars
indicate non-targeted and targeted NP formulations, respectively, selected for in vivo
studies. (C) Biodistribution and (D) tumor accumulation of a targeted NP composed of 14
mol% PLGA-PEG-LIG and non-targeted NP. **Statistically significant by t-test with p <
0.005. Error bars denote ±S.D.
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